Characteristics of COVID-19 disease in multiple sclerosis patients

Affiliations

¹ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
² Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Universal Council of Epidemiology (UCE) Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
³ Universal Council of Epidemiology (UCE) Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
⁴ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Universal Council of Epidemiology (UCE) Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
⁵ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁶ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: shaygannejad@med.mui.ac.ir.
⁷ University of Toronto, St. Michael's Hospital Multiple Sclerosis clinic, Toronto, ON, Canada.

Comment

Mahdi Barzegar et al. Mult Scler Relat Disord. 2020 Oct.

. 2020 Oct:45:102276.

doi: 10.1016/j.msard.2020.102276. Epub 2020 Jun 8.

¹ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
² Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Universal Council of Epidemiology (UCE) Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
³ Universal Council of Epidemiology (UCE) Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
⁴ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Universal Council of Epidemiology (UCE) Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
⁵ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
⁶ Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: shaygannejad@med.mui.ac.ir.
⁷ University of Toronto, St. Michael's Hospital Multiple Sclerosis clinic, Toronto, ON, Canada.

No abstract available

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflict of interest.

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F, Nourbakhsh B, Azimi AR. Safavi F, et al. Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13. Mult Scler Relat Disord. 2020. PMID: 32460086 Free PMC article.

1. Barzegar M., Mirmosayyeb O., Nehzat N., Sarrafi R., Khorvash F., Maghzi A.-.H., Shaygannejad V. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol.-Neuroimmunol. Neuroinflamm. 2020;7 - PMC - PubMed
1. Foerch C., Friedauer L., Bauer B., Wolf T., Adam E.H. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult. Scler. Relat. Disord. 2020 - PMC - PubMed
1. Ghajarzadeh M., Mirmosayyeb O., Barzegar M., Nehzat N., Vaheb S., Shaygannejad V., Maghzi A.H. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult. Scler. Relat. Disord. 2020;43 - PMC - PubMed
1. Mirmosayyeb O., Brand S., Barzegar M., Afshari-Safavi A., Nehzat N., Shaygannejad V., Sadeghi Bahmani D. Clinical Characteristics and Disability Progression of Early-and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. J. Clin. Med. 2020;9:1326. - PMC - PubMed
1. Montero-Escribano P., Matías-Guiu J., Gómez-Iglesias P., Porta-Etessam J., Pytel V., Matias-Guiu J.A. Anti-CD20 and Covid-19 in Multiple Sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult. Scler. Relat. Disord. 2020 - PMC - PubMed